Contineum Therapeutics, Inc.
CTNMDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
PIPE-791 Dose A
Idiopathic Pulmonary Fibrosis
PIPE-505
Sensorineural Hearing Loss
PIPE-307 Dose A
Relapsing Remitting Multiple Sclerosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PIPE-791 Dose A | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
PIPE-505 | Phase 2 | Sensorineural Hearing Loss | - | - |
PIPE-307 Dose A | Phase 2 | Relapsing Remitting Multiple Sclerosis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Contineum Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Contineum Therapeutics, Inc.'s (CTNM) pipeline across Phase 2. Its lead program is PIPE-791 Dose A (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Contineum Therapeutics, Inc.'s next FDA catalyst?→
Contineum Therapeutics, Inc.'s (CTNM) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CTNM biotech catalysts?→
Add CTNM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Contineum Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.